A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles

Abstract

Alzheimer’s disease is defined by the presence of β-amyloid plaques and neurofibrillary tau tangles potentially preceding clinical symptoms by many years. Previously only detectable postmortem, these pathological hallmarks are now identifiable using biomarkers, permitting an in vivo definitive diagnosis of Alzheimer’s disease. 18F-flortaucipir (previously known as 18F-T807; 18F-AV-1451) was the first tau positron emission tomography tracer to be introduced and is the only Food and Drug Administration approved tau positron emission tomography tracer (Tauvid™). It has been widely adopted and validated in a number of independent research and clinical settings. In this review, we present an overview of the published literature on flortaucipir for positron emission tomographyimaging of neurofibrillary tau tangles. We considered all accessible peer-reviewed literature pertaining to flortaucipir through April 30, 2022. We found 474 relevant peer-reviewed publications, which were organized into the following categories based on their primary focus: Typical Alzheimer’s disease, mild cognitive impairment, and pre-symptomatic populations; atypical Alzheimer’s disease; non- Alzheimer’s disease neurodegenerative conditions; head-to-head comparisons with other Tau positron emission tomography tracers; and technical considerations. The available flortaucipir literature provides substantial evidence for the use of this positron emission tomographytracer in assessing neurofibrillary tau tangles in Alzheimer’s disease and limited support for its use in other neurodegenerative disorders. Visual interpretation and quantitation approaches, although heterogeneous, mostly converge and demonstrate the high diagnostic and prognostic value of flortaucipir in Alzheimer’s disease.